Drug is shown to help pancreatic cancer cases
The New York Times: In a clinical trial, the use of Abraxane in addition to gemcitabine, the typical drug for pancreatic cancer, prolonged the lives of patients with advanced pancreatic cancer by almost two months. “The simplicity of Abraxane plus gemcitabine may be attractive to physicians and patients,” said Neal J. Meropol, chief of hematology and oncology.